<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920214-0186</DOCNO><DOCID>920214-0186.</DOCID><HL>   NeoRx Gets Stanford License</HL><DATE>02/14/92</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   NERX</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>DRUG MANUFACTURERS (DRG)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>LICENSING AGREEMENTS (LIC)SCIENCE andamp; TECHNOLOGY (SCN)</NS><RE>CALIFORNIA (CA)NORTH AMERICA (NME)PACIFIC RIM (PRM)UNITED STATES (US)WASHINGTON (WA)</RE><LP>   SEATTLE -- NeoRx Corp. said it acquired an exclusiveworld-wide license from Stanford University for technologydesigned to improve cancer treatments.   The license is for Stanford's patented &quot;pre-targeting&quot;technology, which seeks to increase the safety and efficacyof cancer treatment. The approach is intended to allow moreradiation to reach a tumor with less toxicity to normalorgans. The company said it expects the treatment to be inclinical trials next year, if not sooner. The treatment won'tbe available until &quot;significantly&quot; later, depending on theoutcome of the trials, the company said.</LP><TEXT>   NeoRx is a developer of antibody-based cancer treatmentsand diagnostics.</TEXT></DOC>